1. Introduction

Pharmaceutical optimization platforms are digital systems used by pharmaceutical manufacturers, wholesalers, pharmacies, hospitals, insurers, and healthcare platforms to optimize decisions concerning drug pricing, inventory, distribution, prescribing, patient targeting, promotion, demand forecasting, procurement, and supply allocation.

They increasingly combine:

• artificial intelligence and machine learning;
• real-world and claims data;
• electronic health-record data;
• prescription and dispensing data;
• pharmacy purchasing data;
• physician and patient analytics;
• dynamic pricing and discount systems;
• demand forecasting;
• inventory optimization; and
• automated marketing and recommendation systems.

Demand shaping goes beyond predicting demand. The platform may actively influence the quantity, timing, source, or composition of pharmaceutical demand. For example, an algorithm may recommend particular products to physicians, pharmacies, hospitals, insurers, or patients, alter promotional incentives, prioritize particular products in search results, or adjust discounts and availability.

From a competition-law perspective, the central question is therefore not merely whether a platform has a large market share. The important question is whether control over data + algorithms + distribution + recommendations + incentives allows a firm to distort competitive conditions.

2. Meaning of Pharmaceutical Optimization Platforms

A pharmaceutical optimization platform can be understood as a technological intermediary that transforms large amounts of pharmaceutical-market data into commercial decisions.

Typical inputs

1. Prescription data
2. Patient-treatment data
3. Physician behavior
4. Pharmacy purchasing patterns
5. Hospital procurement information
6. Insurance claims
7. Drug prices
8. Inventory levels
9. Geographic demand
10. Promotional responses
11. Clinical information
12. Competitor information

Typical outputs

The platform may determine:

• which product should be promoted;
• which physician should be targeted;
• how much inventory a pharmacy should maintain;
• which wholesaler should receive supply;
• which products should appear prominently;
• which discounts should be offered;
• how marketing expenditure should be allocated;
• which patients are likely to switch therapies;
• what demand is likely to arise; and
• how supply should respond.

Thus, the platform can become an economic decision-making infrastructure rather than merely a software product.

3. Meaning of Demand Shaping

Traditional demand forecasting asks:

"What will consumers buy?"

Demand shaping asks:

"How can market participants be induced to buy particular products, at particular prices, through particular channels?"

This distinction is extremely important in competition law.

Example

Suppose a dominant pharmaceutical platform observes that physicians prescribing Drug A are likely to switch to Drug B when offered certain discounts.

The platform could:

1. identify vulnerable physicians;
2. predict switching probability;
3. target those physicians;
4. change promotional offers;
5. manipulate recommendation rankings;
6. coordinate inventory;
7. reduce visibility of competing products.

The platform is then not merely forecasting demand. It is engineering demand.

4. Why the Pharmaceutical Sector Is Particularly Sensitive

Pharmaceutical markets possess characteristics that make optimization systems especially powerful.

A. Information asymmetry

Patients normally cannot assess medicines in the same manner as ordinary consumer products.

B. Physician-mediated demand

The person making the prescribing decision is often different from the ultimate consumer.

C. Regulatory barriers

Drug approval, reimbursement, marketing authorization, pharmacovigilance, and distribution regulations can create significant entry barriers.

D. Data concentration

Large platforms may possess enormous datasets concerning:

• prescribing;
• treatment outcomes;
• purchasing;
• reimbursement;
• patient behavior; and
• physician preferences.

E. High switching costs

Hospitals, physicians, pharmacies and insurers may become dependent upon established digital infrastructure.

F. Network effects

More users generate more data, which improves the optimization model, which attracts more users.

This creates a potential data → optimization → market power → more data feedback loop.

5. Competition-Law Theory

The principal competition concerns can be divided into six categories.

I. Exclusionary conduct

A dominant pharmaceutical platform might use its optimization capabilities to disadvantage competing products.

Possible mechanisms include:

• preferential ranking;
• discriminatory recommendations;
• exclusionary rebates;
• tying;
• bundling;
• refusal to provide essential data;
• discriminatory API access;
• foreclosure of competing distributors.

II. Exploitative conduct

The platform could use its informational advantage to charge:

• discriminatory prices;
• excessive fees;
• discriminatory commissions; or
• highly individualized prices.

The legal treatment differs substantially across jurisdictions.

III. Algorithmic coordination

Optimization systems can create risks where competing pharmaceutical firms use similar:

• pricing algorithms;
• demand forecasts;
• inventory systems;
• promotion platforms; or
• third-party optimization providers.

Even without an explicit agreement, algorithms can potentially facilitate parallel price movements or coordinated market behavior.

The legal challenge is distinguishing:

lawful independent algorithmic optimization

from

algorithmically facilitated collusion.

6. Demand Shaping Through Recommendations

A particularly important issue is recommendation bias.

Suppose a platform recommends medicines based on a commercial objective rather than clinical neutrality.

A dominant platform could potentially:

• rank affiliated medicines higher;
• suppress generic alternatives;
• prioritize products generating higher commissions;
• steer physicians toward preferred suppliers;
• manipulate pharmacy purchasing recommendations.

This can transform an apparently neutral digital interface into a competitive gatekeeper.

7. Demand Shaping Through Rebates

Demand shaping can also operate through rebates.

A platform may offer:

"Higher rebate if 80% of purchases are made from the platform's preferred pharmaceutical portfolio."

If the platform possesses substantial market power, such arrangements can potentially create loyalty-inducing effects.

The analysis would consider:

• rebate structure;
• duration;
• foreclosure percentage;
• coverage;
• incremental versus retroactive discounts;
• availability of alternatives;
• market position;
• effects on competitors; and
• objective justifications.

8. Demand Shaping Through Data

Data itself can become a competitive asset.

A dominant platform could possess information about:

• competitors' inventory;
• prescription trends;
• hospital purchasing;
• physician preferences;
• generic substitution;
• patient switching;
• regional demand.

If the platform uses that information to optimize its own pharmaceutical business while withholding equivalent access from competitors, a vertical data advantage may emerge.

This raises questions concerning:

Data access

Should competitors receive access to certain datasets?

Data portability

Can customers transfer their historical purchasing and prescribing information?

Interoperability

Can competing platforms connect to the dominant platform?

Data discrimination

Does the platform provide superior data access to its affiliated products?

9. Pharmaceutical Platforms as Gatekeepers

A platform becomes particularly significant when it controls several stages:

Data collection → Analytics → Recommendation → Procurement → Distribution → Demand generation

Vertical integration can therefore produce a powerful strategic advantage.

For example:

Pharmaceutical manufacturer + optimization software + wholesaler + pharmacy network

may allow the integrated entity to influence both supply and demand.

Competition authorities may therefore examine the entire ecosystem rather than looking at each service separately.

10. Relevant Market Definition

Several relevant markets may exist simultaneously.

Possible markets

1. Pharmaceutical products
2. Pharmaceutical distribution
3. Pharmaceutical wholesaling
4. Pharmacy services
5. Digital prescribing platforms
6. Pharmaceutical analytics
7. Healthcare data services
8. Demand-forecasting software
9. Pharmaceutical advertising technology
10. Clinical decision-support software

The relevant market might therefore be:

the market for pharmaceutical optimization and demand-management platforms

rather than simply the market for medicines.

11. Market Power Indicators

Market share alone may be insufficient.

Authorities may examine:

Data advantages

Does the platform possess unique datasets?

Switching costs

Can customers easily migrate?

Network effects

Does additional participation improve the platform?

Multi-homing

Can pharmacies, physicians, and hospitals simultaneously use competing platforms?

Interoperability

Can competitors connect to the platform?

Vertical integration

Does the platform also manufacture, distribute, insure, or sell medicines?

Algorithmic superiority

Does accumulated data make the optimization system materially more effective?

12. Six Important Case Laws

1. United Brands v Commission

United Brands Company and United Brands Continentaal BV v Commission (Case 27/76)

The European Court of Justice examined dominance, market definition, barriers to entry and abusive conduct.

Relevance

Although the case concerned bananas rather than pharmaceutical technology, it is important because it establishes foundational principles concerning dominant-market power and abusive conduct.

For pharmaceutical optimization platforms, the case can support analysis of whether a technologically sophisticated undertaking possesses sufficient market power to behave independently of customers and competitors.

Application

A platform with:

• dominant data access;
• strong network effects;
• high switching costs; and
• control over pharmaceutical distribution

could potentially satisfy the economic conditions associated with dominance.

13. Hoffmann-La Roche v Commission

Hoffmann-La Roche & Co AG v Commission (Case 85/76)

This is particularly important for pharmaceutical competition law.

The Court considered loyalty-inducing arrangements involving a dominant undertaking.

Principle

A dominant firm has a special responsibility not to allow its conduct to impair genuine undistorted competition.

Relevance to optimization platforms

Imagine a dominant pharmaceutical platform offering customers increasingly attractive rebates for concentrating their purchases on the platform.

If optimization software identifies customer purchasing behavior and automatically calibrates loyalty incentives, the system could make exclusionary rebate strategies significantly more precise.

The digital system therefore potentially amplifies the competitive effects of traditional loyalty arrangements.

14. AstraZeneca v Commission

AstraZeneca AB and AstraZeneca plc v Commission (Case C-457/10 P)

This case concerned abuse of dominance in the pharmaceutical sector, particularly conduct involving regulatory procedures and market protection.

Importance

The case demonstrates that pharmaceutical competition law must take account of the interaction between:

• regulatory systems;
• intellectual property;
• market entry; and
• dominant-firm strategies.

Application to digital optimization

A dominant pharmaceutical platform might similarly use regulatory or informational infrastructure strategically to make entry more difficult.

For example, a platform could potentially:

• restrict access to commercially important data;
• manipulate interoperability;
• make competitors dependent upon proprietary infrastructure; or
• use regulatory-compliance infrastructure to reinforce platform advantages.

15. Google Shopping

Google Search (Shopping), Commission Decision AT.39740; General Court judgment in Google and Alphabet v Commission

This is one of the most important modern cases for understanding ranking and self-preferencing.

The competition concern involved preferential treatment of Google's own comparison-shopping service in search results.

Pharmaceutical analogy

Consider a pharmaceutical optimization platform that simultaneously:

1. operates a medicine-discovery platform;
2. sells pharmaceutical products;
3. provides recommendations to pharmacies; and
4. controls ranking algorithms.

If the platform systematically ranks its own medicines or affiliated suppliers more prominently, competition authorities could examine whether this constitutes an exclusionary strategy.

Key lesson

An algorithmically controlled ranking system can itself become an instrument of competitive discrimination.

16. MEO – Serviços de Comunicações e Multimédia

MEO – Serviços de Comunicações e Multimédia SA v Autoridade da Concorrência (Case C-525/16)

The Court considered discriminatory pricing under Article 102 TFEU.

Importance

Not every difference in treatment automatically constitutes an abuse.

Competition analysis requires attention to whether discriminatory conditions are capable of placing trading partners at a competitive disadvantage.

Pharmaceutical application

An optimization platform might offer different:

• commissions;
• access fees;
• rebates;
• data-access conditions; or
• algorithmic visibility

to different pharmacies or pharmaceutical suppliers.

The legal analysis would need to examine the actual competitive effects rather than treating every price difference as automatically unlawful.

17. Intel v Commission

Intel Corporation Inc. v European Commission (Case C-413/14 P)

Intel concerned rebates offered by a dominant undertaking and became a major authority on assessing whether conduct is capable of producing exclusionary effects.

Relevance

The case is particularly useful for pharmaceutical demand-shaping systems because digital platforms can create extremely sophisticated rebate structures.

An optimization engine could calculate:

• customer elasticity;
• competitor threat;
• switching probability;
• purchasing volume;
• rebate sensitivity.

It could then dynamically determine incentives.

Competition-law issue

The sophisticated nature of the algorithm does not remove the need to assess whether the resulting conduct produces or is capable of producing exclusionary effects.

18. Google Android

Google and Alphabet v Commission — Android (Case T-604/18)

The case involved Google's conduct concerning the Android ecosystem, including tying and restrictions affecting competing search and browser services.

Relevance

It illustrates the importance of ecosystem leverage.

A pharmaceutical optimization platform could potentially operate several interconnected services:

analytics + prescribing + procurement + pharmacy marketplace + advertising + payment + inventory.

The platform might then use dominance in one layer to reinforce another.

This creates potential ecosystem foreclosure.

19. Additional Pharmaceutical Competition-Law Authorities

Several pharmaceutical cases provide useful conceptual support.

GlaxoSmithKline Services Unlimited v Commission

The European courts considered restrictions affecting pharmaceutical distribution and parallel trade.

Relevance: pharmaceutical distribution structures can have competition implications beyond conventional price competition.

Servier

The Commission and EU courts examined patent-related arrangements and potential restrictions on generic entry.

Relevance: competition law can scrutinize strategies that delay or restrict competitive entry in pharmaceutical markets.

Lundbeck

The case concerned agreements involving originator and generic pharmaceutical companies.

Relevance: arrangements affecting potential generic competition can attract substantial scrutiny.

20. Algorithmic Collusion Risk

Demand-shaping platforms can create another problem: coordination between competitors.

Suppose several pharmaceutical manufacturers independently employ the same third-party optimization system.

The system receives information about:

• market demand;
• prices;
• inventory;
• promotions;
• competitors.

If the optimization system recommends similar price responses to each manufacturer, the market may become unusually predictable.

Competition authorities may therefore ask:

1. Who designed the algorithm?
2. What data does it receive?
3. Does it receive competitor-sensitive information?
4. Does the provider coordinate recommendations?
5. Are algorithms independently configured?
6. Can firms override the recommendations?
7. Is there communication between competitors?
8. Is the system deliberately designed to stabilize prices?

21. Tacit Coordination Versus Concerted Practice

A difficult distinction arises between:

Tacit algorithmic parallelism

Competitors independently use algorithms that react predictably to market conditions.

and

Algorithmically facilitated coordination

Competitors use a common system or exchange information in a way that facilitates coordinated conduct.

The second situation raises much stronger competition-law concerns.

22. AI-Based Demand Prediction and Market Foreclosure

AI forecasting can also create barriers to entry.

An incumbent platform with enormous historical data may produce extremely accurate forecasts.

A new entrant, lacking comparable data, may therefore face:

• poorer inventory planning;
• higher wastage;
• lower fulfillment rates;
• less effective targeting;
• higher marketing costs.

This produces a potential data-driven entry barrier.

23. Demand Shaping and Generics

Generic medicines create a particularly interesting application.

Suppose an optimization platform is controlled by an originator pharmaceutical company.

The system could potentially recommend:

branded medicine → preferred

while assigning generic medicines lower visibility.

Competition authorities could examine whether the system:

• manipulates recommendation rankings;
• restricts generic visibility;
• conditions discounts;
• ties products;
• exploits physician information; or
• makes switching artificially difficult.

This could be particularly significant where generic substitution is an important source of competitive pressure.

24. Demand Shaping and Hospitals

Hospital procurement creates another potential problem.

A dominant platform may control:

• tender analytics;
• procurement software;
• inventory management;
• supplier comparison;
• purchasing recommendations.

If the platform also supplies medicines, it could theoretically use the procurement system to influence hospital purchasing decisions.

The resulting issue is vertical foreclosure.

25. Demand Shaping and Pharmacies

For pharmacies, optimization systems may determine:

• stock levels;
• replenishment timing;
• supplier selection;
• product ranking;
• substitution recommendations.

A platform could therefore influence demand indirectly by determining which products are readily available.

This creates an important economic insight:

Control over availability can become control over demand.

A product that is systematically unavailable or poorly positioned may experience reduced demand even if its underlying price and quality remain competitive.

26. Consumer-Welfare Issues

Demand shaping can potentially produce:

Higher prices

Consumers may be steered toward expensive medicines.

Reduced choice

Competing medicines may become less visible.

Reduced innovation

Entrants may find it difficult to acquire sufficient scale.

Reduced quality

Platforms may optimize for commercial metrics rather than clinical value.

Information asymmetry

Patients may not know why a medicine was recommended.

27. Transparency and Explainability

A major competition-law issue is whether an affected business can determine:

Why did the algorithm rank my product below a competitor?

Opaque optimization systems may make it difficult for competitors to establish:

• discrimination;
• exclusion;
• self-preferencing;
• retaliation;
• manipulation; or
• discriminatory access.

Therefore, competition authorities may increasingly require algorithmic auditability in important platform investigations.

28. Remedies

Potential remedies include:

Structural remedies

• divestiture;
• separation of platform and pharmaceutical businesses;
• restrictions on vertical integration.

Behavioral remedies

• non-discrimination;
• transparent ranking;
• access obligations;
• interoperability;
• data portability;
• prohibition of tying;
• restrictions on loyalty rebates.

Technical remedies

• independent algorithmic audits;
• logging requirements;
• API access;
• model documentation;
• explainability obligations;
• independent monitoring.

Data remedies

• data-sharing requirements;
• portability;
• interoperability;
• restrictions on combining datasets.

29. Global Regulatory Perspective

Different jurisdictions may approach the problem differently.

European Union

Article 101 and Article 102 TFEU provide the traditional competition-law framework, increasingly supplemented by digital-platform regulation.

United States

The Sherman Act and Clayton Act provide the principal antitrust framework, with particular importance attached to monopolization, tying, exclusive dealing, mergers and vertical restraints.

United Kingdom

The Competition Act 1998, Enterprise Act 2002 and the newer digital-markets framework provide tools for addressing dominant digital platforms and strategic market power.

Germany

German competition law has developed particularly important rules concerning powerful digital ecosystems and undertakings of paramount significance across markets.

China

The Anti-Monopoly Law increasingly addresses platform economics, data advantages, algorithmic practices and digital-market conduct.

India

The Competition Act 2002, including its developing digital-market enforcement framework, is increasingly relevant where pharmaceutical platforms combine data, marketplace functions, distribution and recommendation systems.

30. Key Competition-Law Questions

A competition authority investigating a pharmaceutical optimization platform should ask:

1. What is the relevant market?
2. Does the platform possess substantial market power?
3. What datasets does it control?
4. Are those datasets replicable?
5. Does the platform operate in adjacent pharmaceutical markets?
6. Does it favor its own products?
7. Does it discriminate against competing suppliers?
8. Does it use loyalty-inducing rebates?
9. Does it restrict interoperability?
10. Does it prevent data portability?
11. Does the algorithm facilitate coordination?
12. Does the system create artificial switching costs?
13. Does demand shaping harm generic competition?
14. Does the platform exploit physician or pharmacy dependency?
15. Are restrictions objectively justified?

31. Conceptual Model

The competitive mechanism can be represented as:

Large Data Pool
↓
AI Optimization
↓
Better Demand Prediction
↓
More Effective Demand Shaping
↓
Higher User Adoption
↓
More Data
↓
Greater Algorithmic Advantage
↓
Higher Switching Costs
↓
Market Power
↓
Potential Foreclosure of Rivals

This is the data–algorithm–demand–market-power feedback loop.

32. Conclusion

Global pharmaceutical optimization platforms represent an important evolution in competition law because they can transform information into market power.

Traditional pharmaceutical competition focused primarily on:

• patents;
• prices;
• distribution;
• rebates;
• generic entry; and
• market shares.

Digital optimization introduces an additional layer:

Who controls the information architecture through which pharmaceutical demand is predicted and shaped?

The most significant risks arise when one undertaking simultaneously controls data, algorithms, recommendations, procurement, distribution and pharmaceutical supply.

The cases involving United Brands, Hoffmann-La Roche, AstraZeneca, Google Shopping, MEO, Intel and Android provide a useful legal framework for analysing dominance, exclusionary rebates, discriminatory treatment, ecosystem leverage, ranking, self-preferencing and pharmaceutical-market foreclosure.